HomeDealsNegotiationsPolicyPipelineMoneyPeopleDataThe WeekPharmTech 100Deal TrackerResearch
Pipeline

STAT+: At AACR, a provocative use of CAR-T, Merck’s new thing and cancer’s geography problem

At AACR, a bold use of CAR-T raises hopes and provocative questions about its use in smoldering multiple myeloma.

By STAT News · Apr 20, 2026 · via STAT News
STAT+: At AACR, a provocative use of CAR-T, Merck’s new thing and cancer’s geography problem

Image: STAT News

Tags
pipelineformat:headlineheadlineSTAT News
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from Pipeline
All Pipeline →
Merck Gains EU Clearance for Enflonsia, a Long-Acting RSV Antibody for Infants
PipelineBriefing
Merck Gains EU Clearance for Enflonsia, a Long-Acting RSV Antibody for Infants
Enflonsia, now cleared across the EU and EEA, promises single-dose, five-month protection against RSV, positio…
Apr 20, 2026
What actually drives speed in complex drug development programs
PipelineBioPharma Dive ↗
What actually drives speed in complex drug development programs
Learn how early coordination across functions, phases and partners can reduce risk and accelerate drug develop…
Apr 20, 2026
STAT+: AACR 2026: More strong data for Revolution Medicines’ KRAS drug
PipelineSTAT News ↗
STAT+: AACR 2026: More strong data for Revolution Medicines’ KRAS drug
You're reading the web version of STAT's popup newsletter, AACR in 30 seconds, your guide to what's happening …
Apr 19, 2026